journal article·2026-07

Dual-targeted NIR-II AIE theranostic nanoparticles disrupt HNRNPC-driven ITGA1+ myCAFs differentiation and immune evasion in oral squamous cell carcinoma

Mengqi Wang, Ziyue Gu, Yujie Shi, Yuanyuan Li, Jiayi Zhang, Mengyao Wang, Zhiyong Wang, Laikui Liu, Ben Zhong Tang, Ming Zhang, Weiwen Zhu

Biomaterials· Volume 330
Publisher page

Abstract

Oral squamous cell carcinoma (OSCC) remains a therapeutic challenge due to its aggressive metabolism-driven progression and immunosuppressive tumor microenvironment (TME). Through proteomic and transcriptomic analyses, we identified HNRNPC as a novel driver of OSCC progression via aberrant glycolysis and TGF-β-mediated differentiation of ITGA1+ myofibroblastic cancer-associated fibroblasts (myCAFs), which directly induce CD8+ T cell exhaustion. Given the lack of strategies that simultaneously target both tumor and stromal compartments, we engineered a theranostic solution: Near-infrared-II (NIR-II) imaging-guided aggregation-induced emission nanoparticles (AIE NPs) dually conjugated with antibodies against HNRNPC and ITGA1 (NPs-H-I). Studies using molecular experiments, single-nucleus sequencing (snRNA-seq), allograft models, and clinical specimens confirmed that HNRNPC-high OSCCs are enriched with ITGA1+ myCAFs and exhausted CD8+ T cells, correlating with poor patient survival. The developed NPs-H-I demonstrated specific accumulation in tumors, enabling precise NIR-II imaging. Upon 808 nm laser irradiation, NPs-H-I elicited potent photodynamic therapy (PDT), selectively eliminating HNRNPC-high tumor cells and ITGA1+ myCAFs, which robustly inhibited tumor growth and restored anti-tumor immunity in murine models. Our work not only delineates the HNRNPC-ITGA1 axis as a novel metabolic-immune checkpoint in OSCC but also establishes a versatile and translatable precision medicine platform capable of disrupting this pathway for effective combination therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Cells and Metastasis · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. Oral cancer: etiology and risk factors: a review10.4103/0973-1482.186696 ↗
2. Oral cancer: genetics and the role of precision medicine10.1016/j.soc.2019.08.010 ↗
3. "Omics" in oral cancer: new approaches for biomarker discovery10.1016/j.archoralbio.2017.12.003 ↗
4. Hallmarks of cancer: new dimensions10.1158/2159-8290.CD-21-1059 ↗
5. The hallmarks of cancer metabolism: still emerging10.1016/j.cmet.2022.01.007 ↗
6. (mt), and the complexity of mitochondrial DNA landscapes in cancer10.1158/0008-5472.CAN-19-1395 ↗
7. Mitohormesis primes tumor invasion and metastasis10.1016/j.celrep.2019.04.095 ↗
8. lncRNA CYTOR promotes aberrant glycolysis and mitochondrial respiration via HNRNPC-mediated ZEB1 stabilization in oral squamous cell carcinoma10.1038/s41419-022-05157-1 ↗
9. Metabolic barriers to cancer immunotherapy10.1038/s41577-021-00541-y ↗
10. Influence of tumour micro-environment heterogeneity on therapeutic response10.1038/nature12626 ↗
11. Foxp3 Reprograms T cell metabolism to function in Low-Glucose, high-lactate environments10.1016/j.cmet.2016.12.018 ↗
12. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer10.1016/j.cmet.2018.04.022 ↗
13. Cancer: an oxidative crosstalk between solid tumor cells and cancer associated fibroblasts10.1155/2016/4502846 ↗
14. The biology and function of fibroblasts in cancer10.1038/nrc.2016.73 ↗
15. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins10.1016/j.semcancer.2019.08.004 ↗
16. The matrix in cancer10.1038/s41568-020-00329-7 ↗
17. A framework for advancing our understanding of cancer-associated fibroblasts10.1038/s41568-019-0238-1 ↗
18. TGF-β and the tissue microenvironment: relevance in fibrosis and cancer10.3390/ijms19051294 ↗
19. Targeting integrin pathways: mechanisms and advances in therapy10.1038/s41392-022-01259-6 ↗
20. Myofibroblast TGF-β activation measurement in vitro10.1007/978-1-0716-1382-5_6 ↗
21. CD8(+) T cell differentiation and dysfunction in cancer10.1038/s41577-021-00574-3 ↗
22. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy10.1038/s41416-020-01048-4 ↗
23. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8(+) T cell exhaustion during metastasis10.1111/cas.15033 ↗
24. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients10.1172/JCI46102 ↗
25. Photodynamic therapy of cancer: an update
26. Harnessing the power of aggregation-induced emission luminogens: From bright probes to theranostic platforms in biomedicine10.1016/j.ccr.2025.217553 ↗
27. Aggregation-Induced emission (AIE), life and health10.1021/acsnano.3c03925 ↗
28. Aggregation-Induced emission nanoparticles for single near-infrared light-triggered photodynamic and photothermal antibacterial therapy10.1021/acsnano.2c00734 ↗
29. TGF-β signaling in the tumor metabolic microenvironment and targeted therapies10.1186/s13045-022-01349-6 ↗
30. TGF-β links glycolysis and immunosuppression in glioblastoma
31. Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion10.3389/fimmu.2022.971045 ↗
32. Molecular and cellular insights into T cell exhaustion10.1038/nri3862 ↗
33. Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression10.1016/j.immuni.2014.08.012 ↗
34. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: a systematic review and meta-analysis10.1002/cam4.2510 ↗
35. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials10.1177/1758835920937612 ↗
36. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions10.1186/s12943-021-01489-2 ↗
37. Rhythmic mild photothermal therapy enhancing anti-PD-L1 response for oral squamous cell carcinoma immunotherapy10.1016/j.cej.2024.150908 ↗
38. Recent advances in aggregation-induced emission materials and their biomedical and healthcare applications10.1002/adhm.202101055 ↗
39. Brain-Targeted aggregation-induced-emission nanoparticles with near-infrared imaging at 1550 nm boosts orthotopic glioblastoma theranostics10.1002/adma.202106082 ↗
40. Powerful synergy of traditional Chinese medicine and aggregation-induced emission-active photosensitizer in photodynamic therapy10.1021/acsnano.3c04342 ↗
41. Structure and functions of Aggregation-Induced Emission-Photosensitizers in anticancer and antimicrobial theranostics10.3389/fchem.2022.984268 ↗
42. The genome sequence archive family: toward explosive data growth and diverse data types10.1016/j.gpb.2021.08.001 ↗
43. Database resources of the National Genomics Data Center, China National Center for bioinformation in 202210.1093/nar/gkab951 ↗